PD-1/PD-L1 Inhibitors in Stage IV Non-Small Cell Lung Cancer - A Single Medical Center Experience

Kuan-Chih Kuo ； Wen-Jui Wu ； Sheng-Hsiung Yang ； Jian Su ； Chia-Te Yen

《胸腔醫學》 35卷3期 (2020/09) Pp. 116-121

摘要

Introduction: Information about the real-world efficacy of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors in the treatment of stage IV lung cancer is limited in Taiwan. Here, we report the experience of a medical center in Taiwan. Methods: Patients diagnosed with lung cancer and treated with PD-1/PD-L1 inhibitors were identified. We recorded the characteristics of the patients, treatment efficacy, and side effects, and analyzed variables related to treatment outcome. Results: From September 2016 to October 2019, 52 lung cancer patients received PD-1/ PD-L1 inhibitors. After exclusion, 38 patients were included for final analysis. Progression-free survival (PFS) was 6.2 months (95% CI, 5.3 to 7.1 months), and overall survival (OS) had not been reached at the time of analysis. Patients that had progressive disease at 2 months after their first PD-1/PD-L1 inhibitors treatment had significantly shorter PFS and OS than patients with stable disease or a partial response. Conclusion: The efficacy of PD-1/PD-L1 inhibitors in this real-world analysis was comparable to that reported in previous clinical trials. Response at 2 months after initiation of immune checkpoint inhibitors is a good predictor for PFS and OS.

關鍵字

immunotherapy ； PD-1/PD-L1 inhibitors ； non-small cell lung cancer